Principal Financial Group Inc Aclaris Therapeutics, Inc. Transaction History

Principal Financial Group Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$0.92 - $1.44 $1,623 - $2,541	-1,765 Reduced 9.09%	17,654 $21,000
Q4 2023 Feb 07, 2024	BUY	$0.64 - $6.49 $418 - $4,244	654 Added 3.49%	19,419 $20,000
Q3 2023 Nov 02, 2023	SELL	$6.56 - $10.95 $2,414 - $4,029	-368 Reduced 1.92%	18,765 $128,000
Q2 2023 Aug 07, 2023	BUY	$7.89 - $10.64 $17,358 - $23,408	2,200 Added 12.99%	19,133 $198,000
Q1 2023 May 09, 2023	SELL	$7.07 - $17.95 $9,014 - $22,886	-1,275 Reduced 7.0%	16,933 $136,000
Q4 2022 Feb 09, 2023	BUY	$14.33 - $18.37 $25,951 - $33,268	1,811 Added 11.04%	18,208 $286,000
Q3 2022 Nov 09, 2022	BUY	$13.07 - $18.22 $3,136 - $4,372	240 Added 1.49%	16,397 $259,000
Q2 2022 Aug 10, 2022	SELL	$10.16 - $17.08 $163,535 - $274,919	-16,096 Reduced 49.91%	16,157 $226,000
Q1 2022 May 09, 2022	SELL	$9.74 - $17.92 $128,100 - $235,683	-13,152 Reduced 28.97%	32,253 $556,000
Q4 2021 Feb 09, 2022	SELL	$12.27 - $18.49 $93,129 - $140,339	-7,590 Reduced 14.32%	45,405 $660,000
Q3 2021 Nov 09, 2021	BUY	$13.38 - $18.8 $117,730 - $165,421	8,799 Added 19.91%	52,995 $954,000
Q2 2021 Aug 10, 2021	BUY	$17.08 - $29.6 $754,867 - $1.31 Million	44,196 New	44,196 $776,000

50.7M

30.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $255M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.